kelatorphan has been researched along with Allodynia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crain, SM; Shen, KF | 2 |
2 other study(ies) available for kelatorphan and Allodynia
| Article | Year |
|---|---|
Low doses of cyclic AMP-phosphodiesterase inhibitors rapidly evoke opioid receptor-mediated thermal hyperalgesia in naïve mice which is converted to prominent analgesia by cotreatment with ultra-low-dose naltrexone.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Analgesia; Analgesics; Animals; Cyclic AMP; Dipeptides; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Hyperalgesia; Male; Mice; Naltrexone; Narcotic Antagonists; Nociceptors; Phosphodiesterase Inhibitors; Receptors, G-Protein-Coupled; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu; Signal Transduction; Time Factors | 2008 |
Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
Topics: Analgesics, Opioid; Animals; Chronic Disease; Dipeptides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; G(M1) Ganglioside; Hyperalgesia; Male; Mice; Morphine; Morphine Dependence; Naloxone; Naltrexone; Narcotic Antagonists; Nociceptors; Opioid Peptides; Receptors, Opioid, kappa; Substance Withdrawal Syndrome | 2007 |